Mirum
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
950 Tower Ln Ste 1050, Foster City, Cali...Phone Number
(650) 667-4085Website
www.mirumpharma.comRevenue
$569.6 MillionStock Symbol
MIRMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
5
1
1
1
1
About Mirum
Mirum Pharmaceuticals is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) - conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their liveRead more
Mirum Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mirum your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Mirum launches new products
Website visits: Recent activity has been detected on your website
Mirum, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Mirum
Check out if Mirum is spiking on competitors!
Earning: See what the market has to say on Mirum recently announced quarterly report
Click to see if Mirum had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Mirum has new funding data
Check if Mirum has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Mirum
Compare insights from companies similar to Mirum, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.9M
51-200
Private
$300M
2016
RC
Ryan CarteExecutive Vice President & General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Mirum is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mirum is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mirum.
Mirum financials insights
Gather financial insights about Mirum, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$68.5M
Mirum Tech Stack
A closer look at the technologies used by Mirum
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Events, Pharmaceuticals
Earnings
Mirum has reported total net product sales of approximately $160 million for Q1, including LIVMARLI net product sales of $84 million in the US and $30 million internationally, with bile acid medicines contributing $46 million.
Earnings, Finance
Earnings
Mirum has indicated that GAAP profitability is expected to be pushed out to 2028 due to significant R&D investment in brelovitug and volixibat, while reiterating that the company expects to be operating cash flow positive in 2027.
Earnings, Research & Development, Business Finance, Finance
Earnings
Earnings, Accounting, Financial Reporting, Finance, Financial Operations
Mirum News & Media
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech companyMirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company’s businPrediction: Buying This Biotech Stock Today Could Set You Up for Life
This small biotech could grow much larger with some good news from its pipeline.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mirum
Sign Up For FreeTo access detailed company insights
Mirum Pharmaceuticals is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) - conditions with a profound and devastating impact on quality of life for young patients and their families. Untre... Read More
